Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05268250 · ClinicalTrials.gov registry record · NA
Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families
A NA study of Type 1 Diabetes, sponsored by Nemours Children's Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 180
- Enrollment target
- 2
- Study locations
NCT05268250: Recruiting NA study of Type 1 Diabetes, sponsored by Nemours Children's Clinic.
NCT05268250 is a NA study of Type 1 Diabetes that is actively recruiting participants, run by Nemours Children's Clinic. The registered enrollment target is 180 participants, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05268250, a NA study of Type 1 Diabetes, is actively recruiting participants, sponsored by Nemours Children's Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
- 2
- Study locations
Study Summary
This R01 is in response to RFA-DK-19-021, Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes. The objective is to test the feasibility and acceptability of a novel, practical, and potentially scalable screen to treat program for diabetes distress in families of school-age children with T1D (called Remedy to Diabetes Distress \[R2D2\]) and to test the initial efficacy of R2D2 to reduce diabetes distress to improve children's glycemic control.
Primary Outcome
proxy measure of average glycemic levels over 10-12 weeks
Conditions Studied
Interventions
- BEHAVIORAL R2D2 mHealth intervention
Study Locations (2)
Florida
- Nemours Children's Health - Jacksonville
Missouri
- Children's Mercy Kansas City - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2024-02-26 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
What NCT05268250 shows while recruiting
NCT05268250 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which R2D2 mHealth intervention is the first listed.
NCT05268250 reports a single indexed study location in Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT05268250 about?
NCT05268250 is a clinical study titled "Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families". This R01 is in response to RFA-DK-19-021, Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes. The objective is to test the feasibility and acceptability of a novel, practical, and potentially scalable screen to treat program for diabetes distress in families of school-age chi...
What is the current status of trial NCT05268250?
This trial is currently recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2024-02-26. Estimated completion is 2026-08-31.
What conditions does trial NCT05268250 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT05268250?
The interventions under investigation include: R2D2 mHealth intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05268250?
This trial is sponsored by Nemours Children's Clinic, which has 108 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05268250 being conducted?
This trial has 2 study locations across Florida, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05268250's enrollment target sits among peer trials
180 32nd of 198 higher than 166 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
AIDANET Pediatrics
RECRUITING · NA
-
A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
RECRUITING · NA
-
Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery
RECRUITING · NA
-
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
RECRUITING · NA
-
Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI